-
Industry TrendsGovernment Goodwill as a Competitive Edge: Strategic Takeaways from South Korea’s Pharma Partnerships
South Korea’s partnerships with global pharma giants reveal a powerful strategic lesson: companies that build early government goodwill, track policy signals, and diversify geographically position themselves for long‑term influence and competitive advantage.Dieu Anh Nguyen • -
Industry TrendsHow the Iran Conflict Could Disrupt Global Pharmaceutical Supply Chains
The U.S-Iran conflict highlights how fragile pharmaceutical supply chains remain, with energy prices, shipping routes and manufacturing capacity all vulnerable to geopolitical disruption.Kyra • -
Market TrendThe Legal Logic Behind Big Pharma's MASH Buying Spree
The rush to secure MASH assets shows how intellectual property rules can drive strategic decisions—pushing companies toward acquisition over collaboration in the race for next-generation combination therapies.Dieu Anh Nguyen • - M&A
The Push Toward Oral Obesity and Diabetes Biologics
Novo Nordisk's new partnership with Vivtex aims to develop next-generation oral biologics for obesity and diabetes, signalling a major shift toward more accessible, non-injectable metabolic treatments.Miriam Saif •
-
M&AEli Lilly Strengthens In Vivo Platform with Orna Therapeutics Acquisition
Eleanor G • -
Clinical TrialsWhy Phase II Trials Break More Biotech Companies Than Bad Science
Kyra • -
Market TrendPharma's Big Bet on Sports Advertising: Lessons from the Super Bowl and Olympics
Dieu Anh Nguyen • - Market Trend
Alzheimer's Therapeutics: Renewed Investment and Emerging Opportunities
Miriam Saif • -
PharmaceuticalSkinny labels – the cause of disputes between drug makers
Dieu Anh Nguyen • -
Market TrendOperational Decisions Becoming Strategic Signals in Biotech
Miriam Saif • -
Market TrendAstraZeneca’s Asia Gamble
eleanor g • -
Case StudyUS–UK Pharma Deal Reprices the UK Market
Sisir Kalavala • -
Case StudyHow a Biological Database Company Sells Electronic Shovels in the AI Gold Rush
Dieu Anh Nguyen • -
PharmaceuticalNew EU Drug Rules: A Game-Changer for Start-Ups
Miriam Saif • -
PharmaceuticalNovo Nordisk’s Path Through Recent Challenges
Eleanor G • -
Case StudyFlagship Pioneering: Reinventing Venture Capital in Biopharma
Dieu Anh Nguyen • - Market Trend
Fruit Flies in Drug Discovery: Faster, Cheaper, Smarter Early Screening
Miriam Saif • -
Case StudyHow Eli Lilly reached a $1 Trillion Valuation
eleanor g • -
M&AJohnson & Johnson's Acquisition of Halda Therapeutics: Expanding Precision Oncology Capability
Sisir Kalavala • -
M&APfizer-Novo-Metsera dispute: lessons to learn on biotech-pharma M&A deals
Dieu Anh Nguyen • - BioTech
How AI and Automation are Opening the Door to Biotech Innovators
Miriam Saif • -
Case StudyBrexit and the UK Biopharma Industry
Eleanor G • -
Spin-OffsKimberly-Clark's $32 Billion Acquisition of Kenvue: A Strategic Realignment in Global Healthcare
Sisir Kalavala • -
Market TrendWhy Pharma Companies are Investing in U.S. Direct-to-Consumer Sales: Insights on Pharmaceutical Distribution
Dieu Anh Nguyen • - BioTech
Gut Instincts: How Microbiome Science Can Reshape Addiction Medicine
Miriam Saif • -
Case StudyHaleon’s Success Three Years After Leaving GSK
Eleanor G • -
Spin-OffsJohnson & Johnson's DePuy Synthes Spin-Off
Sisir Kalavala • -
Case StudyThree FDA Rejections Later: The Lessons Behind Xspray Pharma’s Dasynoc™ Setback
Dieu Anh Nguyen • -
PharmaceuticalGSK Enters a New Era Under Incoming CEO Luke Miels
Sisir Kalavala • -
BioTechWhat to Take Away From Takeda's Discontinuation of Cell therapy?
Dieu Anh Nguyen •
